An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.

被引：1
|
作者：
Decoster, Lore
Cappoen, Nadia
Aftimos, Philippe Georges
Raicevic, Gordana
Rolfo, Christian Diego
Rottey, Sylvie
Duhoux, Francois P.
Collignon, Joelle
Hebrant, Aline
Vandenbulcke, Marc
De Greve, Jacques
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[3] Belgian Soc Med Oncol, Brussels, Belgium
[4] Univ Antwerp Hosp, Edegem, Belgium
[5] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[6] Clin Univ St Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium
[7] Catholic Univ Louvain, Inst Rech Expt & Clin Pole MIRO, Brussels, Belgium
[8] CHU Sart Tilman, Liege, Belgium
[9] Wetenschappelijk Inst Volksgezondheid Belgie, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2615
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer
    Zhang, Tongtong
    Li, Qing
    Chen, Shanshan
    Luo, Yang
    Fan, Ying
    Xu, Binghe
    ONCOTARGET, 2017, 8 (22) : 36750 - 36760
  • [42] A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Zhang, Pin
    Wang, Lin
    Zhen, Yueying
    Wang, Zhihong
    Zhang, Hesheng
    Jones, Richard
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
  • [43] Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial
    Fan, Yun
    Chen, Jianhua
    Zhou, Chengzhi
    Wang, Huijuan
    Shu, Yongqian
    Zhang, Jacky
    Hua, Hairui
    Huang, Dennis Chin-Lun
    Zhou, Caicun
    LUNG CANCER, 2020, 147 : 209 - 213
  • [44] Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers
    Kamaljeet Singh
    Umadevi Tantravahi
    Michele M. Lomme
    Terese Pasquariello
    Margaret Steinhoff
    C. James Sung
    Breast Cancer Research and Treatment, 2016, 157 : 405 - 411
  • [45] Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers
    Singh, Kamaljeet
    Tantravahi, Umadevi
    Lomme, Michele M.
    Pasquariello, Terese
    Steinhoff, Margaret
    Sung, C. James
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (03) : 405 - 411
  • [46] A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer
    Yang, Zandong
    Tchekmedyian, Nishan
    Chu, David T.
    Reddy, Guru
    Bhat, Gajanan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTO)
    Hirashima, T.
    Nakagawa, K.
    Kashii, T.
    Kubo, A.
    Sasaki, J.
    Tanaka, K.
    Sato, S.
    Kurata, T.
    Tamura, K.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer
    Gandhi, Shipra
    Forsyth, Peter A. J.
    Opyrchal, Mateusz
    Ahmed, Kamran A.
    Attwood, Kristopher
    Levine, Ellis Glenn
    O'Connor, Tracey L.
    Early, Amy P.
    Fenstermaker, Robert Alan
    Prasad, Dheerendra
    Takabe, Kazuaki
    Czerniecki, Brian J.
    Kalinski, Pawel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] A Phase I/Il Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3 in Patients with Solid Tumors
    Calvo, Emiliano
    Alsina, Maria
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    Tabernero, Josep
    de Vries-Schultink, Aurelia
    Boni, Valentina
    Doger, Bernard
    Geuijen, Cecile
    Doornbos, Robert
    Bol, Kees
    Westendorp, Martine
    Throsby, Mark
    Bakker, Lex
    Shamsili, Setareh
    CANCER RESEARCH, 2016, 76
  • [50] BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
    Nam, Soo Kyung
    Yun, Sumi
    Koh, Jiwon
    Kwak, Yoonjin
    Seo, An Na
    Park, Kyoung Un
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Woo Ho
    Lee, Hye Seung
    PLOS ONE, 2016, 11 (03):
12345